Mirum Pharmaceuticals
Update in progressMIRM (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Mirum Pharmaceuticals is a biopharma focused on rare and orphan diseases. Its lead product, LIVMARLI (maralixibat), is an oral IBAT inhibitor approved for cholestatic pruritus in Alagille syndrome. The company also markets Cholbam for bile acid synthesis and certain peroxisomal disorders, and Chenodal for radiolucent gallstones, with development in other programs including Volixibat, Brelovitug, and MRM-3379. Founded 2018, based in Foster City, CA.
Company score
- Sentiment
- 0.45
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.52
- Governance
- 0.09
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.17
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.31
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!